Literature DB >> 11910068

Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.

Andrew H Briggs1, Bernie J O'Brien, Gordon Blackhouse.   

Abstract

As many more clinical trials collect economic information within their study design, so health economics analysts are increasingly working with patient-level data on both costs and effects. In this paper, we review recent advances in the use of statistical methods for economic analysis of information collected alongside clinical trials. In particular, we focus on the handling and presentation of uncertainty, including the importance of estimation rather than hypothesis testing, the use of the net-benefit statistic, and the presentation of cost-effectiveness acceptability curves. We also discuss the appropriate sample size calculations for cost-effectiveness analysis at the design stage of a study. Finally, we outline some of the challenges for future research in this area-particularly in relation to the appropriate use of Bayesian methods and methods for analyzing costs that are typically skewed and often incomplete.

Entities:  

Mesh:

Year:  2001        PMID: 11910068     DOI: 10.1146/annurev.publhealth.23.100901.140534

Source DB:  PubMed          Journal:  Annu Rev Public Health        ISSN: 0163-7525            Impact factor:   21.981


  100 in total

1.  Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial.

Authors:  Tazeen H Jafar; Muhammad Islam; Rasool Bux; Neil Poulter; Juanita Hatcher; Nish Chaturvedi; Shah Ebrahim; Peter Cosgrove
Journal:  Circulation       Date:  2011-09-19       Impact factor: 29.690

2.  Modeled cost-effectiveness of the Experience Corps Baltimore based on a pilot randomized trial.

Authors:  Kevin D Frick; Michelle C Carlson; Thomas A Glass; Sylvia McGill; George W Rebok; Crystal Simpson; Linda P Fried
Journal:  J Urban Health       Date:  2004-03       Impact factor: 3.671

3.  The incremental cost-effectiveness of engaging private practitioners to refer tuberculosis suspects to DOTS services in Jogjakarta, Indonesia.

Authors:  Yodi Mahendradhata; Ari Probandari; Riris A Ahmad; Adi Utarini; Laksono Trisnantoro; Lars Lindholm; Marieke J van der Werf; Michael Kimerling; Marleen Boelaert; Benjamin Johns; Patrick Van der Stuyft
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

4.  Cost effectiveness of a program to promote screening for cervical cancer in the Vietnamese-American population.

Authors:  John F Scoggins; Scott D Ramsey; J Carey Jackson; Victoria M Taylor
Journal:  Asian Pac J Cancer Prev       Date:  2010

Review 5.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

Review 6.  Information created to evade reality (ICER): things we should not look to for answers.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

7.  Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.

Authors:  Michael Spencer; Andrew H Briggs; Ronald F Grossman; Laureen Rance
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Cost-effectiveness of lung volume reduction surgery.

Authors:  Scott D Ramsey; Sean D Sullivan; Robert M Kaplan
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

9.  The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis.

Authors:  M J Harrison; L M Davies; N J Bansback; M J McCoy; S M M Verstappen; K Watson; D P M Symmons
Journal:  Qual Life Res       Date:  2009-09-24       Impact factor: 4.147

Review 10.  Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Authors:  Stefan Vegter; Cornelis Boersma; Mark Rozenbaum; Bob Wilffert; Gerjan Navis; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.